EYEXORA SETS UP SINGAPORE CO-HEADQUARTERS TO ACCELERATE OPHTHALMIC INNOVATION WORLDWIDE

KUALA LUMPUR, Nov 6 (Bernama) -- Eyexora, a biotechnology company developing innovative therapies for ophthalmic diseases, has established its co-headquarters in Singapore as part of its global expansion and commitment to advancing eye health worldwide.

The company’s seed financing was led by Singapore-based global life sciences investor ClavystBio, while its initial programmes have been in-licensed from the Singapore Eye Research Institute (SERI).

Eyexora in a statement said the new Singapore headquarters would serve as a gateway to its growing activities across the Asia-Pacific region, supporting clinical development, research collaborations and regional partnerships.

The expansion also strengthens Eyexora’s collaboration with SERI, a long-standing partner in ophthalmic research and innovation.

Eyexora Chief Executive Officer (CEO) and Vice Chair of the Board, Dr Theresa Heah said Singapore has become a global centre for ophthalmic research and innovation.

“This new co-headquarters positions Eyexora at the heart of Asia-Pacific’s biomedical ecosystem and strengthens our collaboration with SERI,” she said.

Its Chairman of the Board, Dr William J. Link said the move reflects the company’s vision to build a global ophthalmic enterprise, citing Singapore’s strong research infrastructure and innovation culture as key enablers.

Meanwhile, ClavystBio CEO, Dr Khoo Shih said Eyexora’s new co-headquarters underscores Singapore’s leadership in ophthalmology research and its growing stature as a global life sciences hub.

Last month, Eyexora launched its second spoke company, Y.ora Vision Inc, which focuses on developing next-generation ophthalmic medical devices for glaucoma. This complements its first spoke company, Serenora Therapeutics Inc, which develops treatments for eye diseases.

Eyexora’s Singapore base complements its United States headquarters in New York and will anchor the company’s Asia-Pacific operations, including clinical, scientific, and strategic functions.

-- BERNAMA